Haemonetics Corporation

Globus Medical reported second-quarter revenues of $789.6 million, up 5.9% year on year and 0.9% above analysts' expectations, as the medical devices and supplies specialty industry posted a strong quarter overall. The company also beat analysts' full-year EPS guidance estimates and their quarterly EPS estimates, with President and Chief Executive Officer Keith Pfeil citing 6% overall revenue growth, or 9% excluding Nevro, driven by share gains in US Spine, up 7%, and International Spine, up 14% as-reported and 12% on a constant currency basis. Despite the beat, Globus Medical shares are down 8.8% since reporting and trade at $73.94. Across the seven specialty medical device stocks tracked, group revenues beat consensus by 2.1%, with Inspire Medical Systems posting the highest full-year guidance raise of the group and STAAR Surgical delivering the biggest analyst estimate beat and fastest revenue growth, while Enovis turned in the weakest performance against estimates and the weakest guidance update. Inspire Medical Systems shares are up 32.3% since reporting at $69.08, Haemonetics is up 27.8% at $106.86, STAAR Surgical is down 21.8% at $19.87, and Enovis is down 39.6% at $18.24.

Bank of America upgraded Haemonetics to Buy from Neutral on Thursday, citing a recent supply deal the blood management solutions provider signed with Australian biopharma company CSL Limited. The non-exclusive deal follows CSL's decision to terminate its plasma supply agreement with Haemonetics in 2021 and carries no minimum purchase requirements, BofA analyst Joanne Wuensch wrote. Wuensch said that in a healthy plasma market, the return of the CSL contract in the US market should provide upside to organic revenue growth, operating margins, and EPS over the next several years, and she raised her price target on Haemonetics to $123 from $92 per share. Haemonetics, based in Boston, Massachusetts, disclosed the deal last month and said it will report the financial impact on fiscal 2027 results alongside its fiscal second-quarter earnings, scheduled for November.

Haemonetics shares rose about 7% in premarket trading after the company disclosed a supply agreement with Australian biopharma CSL Limited. Under the non-exclusive deal, CSL Plasma will use Haemonetics' NexSys PCS devices with Persona PLUS technology and purchase related disposables in the U.S. CSL, which operates one of the world's largest plasma collection networks, is also expected to roll out the devices and disposables across some of its U.S. plasma collection centers. Haemonetics did not update its fiscal 2027 outlook, citing uncertain implementation timing, and plans to discuss the financial impact during its second-quarter fiscal 2027 earnings call in November.

Haemonetics reported first quarter fiscal 2027 results with sales of US$339.38 million and net income of US$33.01 million, alongside a US$391.25 million shelf registration tied to an ESOP related stock offering. The company's recent earnings beat, higher revenue guidance and fresh clinical data around VASCADE MVP XL have coincided with a strong 90 day share price return of 61.31%, while the 1 year total shareholder return of 68.96% signals building momentum. Haemonetics closed at $90.80, and the most followed narrative places fair value at $96.90 using a discounted cash flow framework with an 8.0% range discount rate, implying the stock is 6.3% undervalued. Enterprise-wide portfolio transformation, highlighted by the divestiture of low-margin businesses, disciplined capital deployment, and ongoing investment in automation and digital solutions, is driving substantial gross and operating margin expansion with guidance of 26–27% for FY26. However, the story could change quickly if competition bites into NexSys, TEG or VASCADE, or if U.S.-focused demand slows and exposes product concentration.

Haemonetics reported second-quarter revenue of $339.4 million, beating analyst estimates of $330.2 million, with adjusted earnings per share of $1.14 versus expectations of $1.08. During the earnings call, analysts questioned management on topics including share gains in Interventional Technologies, gross margin progression, and the adoption curve for the Persona PLUS plasma device. CEO Christopher Simon said the Persona PLUS rollout is ahead of schedule and that there is no evidence of capital budget tightening affecting TEG placements. CFO James D'Arecca attributed expected margin expansion to stable SG&A and favorable product mix from Persona PLUS.

Haemonetics reported first quarter revenue of $339 million, increasing 6% reported and organic, and raised its full-year fiscal 2027 guidance. Adjusted earnings per diluted share increased 4% to $1.14. Plasma revenue grew 8% organic, driven by double-digit growth in disposables globally and the rollout of Persona PLUS. MedSurg revenue increased 6% year-over-year reported and organic to $148 million, with Blood Management Technologies growing 8% organically and Vascular Closure up low-double-digits. The company now expects fiscal 2027 reported revenue growth of 5% to 8% and organic growth of 4% to 7%, while reaffirming free cash flow conversion of approximately 80% of adjusted net income.

Haemonetics Corporation has elected Martin Madaus to its Board of Directors, effective July 24, 2026. Dr. Madaus brings more than 30 years of leadership experience in diagnostics and life sciences tools, currently serving as Senior Operating Executive at The Carlyle Group. He previously led Ortho Clinical Diagnostics as Chairman and CEO, and Millipore Corporation as Chairman, President and CEO, where he oversaw its acquisition by Merck KGaA. He also serves as Chair of Repligen Corporation and as a board member of Azenta, Inc. Haemonetics Chair Ellen Zane stated that his operational and strategic expertise will support the company's growth and long-term value creation.

The global apheresis market is projected to grow from USD 3.02 billion in 2026 to USD 4.41 billion by 2031, at a compound annual growth rate of 7.9%. Disposables hold the largest product share, driven by recurring demand from blood collection and therapeutic procedures. Plasmapheresis leads by procedure, supported by rising demand for plasma-derived therapies and increasing plasma donations. North America maintained the largest regional market share in 2025, reflecting high disease prevalence and broad adoption of apheresis technologies. Key players include Terumo Corporation, Fresenius SE & Co. KGaA, Haemonetics Corporation, and Becton, Dickinson and Company.

Haemonetics Corporation's Plasma franchise returned to growth in the fourth quarter of fiscal 2026, with revenues of $130 million, up 3% on a reported basis and 13% on an organic basis excluding CSL. The company's NexSys PCS plasma collection system continues to thrive, and Haemonetics signed new long-term agreements with BioLife and Grifols in fiscal 2025. However, a debt-burdened balance sheet remains a concern, with long-term debt of $1.22 billion and a debt-to-capital ratio of 50.2% at the end of the fiscal fourth quarter. The Zacks Consensus Estimate for fiscal 2026 earnings has moved south 1 cent to $5.22 per share in the past 30 days, while the revenue estimate is pegged at $1.40 billion, indicating a 4.9% decrease from the year-ago reported number. Haemonetics shares have lost 2.4% over the past year, compared with the industry's decline of 29.5%.

The global therapeutic apheresis market is projected to grow from USD 3.84 billion in 2025 to USD 8.94 billion by 2035, at a compound annual growth rate of 7.9%, according to a new report by Healthcare Foresights. The market was valued at approximately USD 4.18 billion in 2026. Growth is driven by the rising prevalence of chronic and autoimmune diseases, technological advancements in automated apheresis systems, and expanding applications in regenerative medicine and CAR-T therapies. North America currently holds the largest market share, while the Asia Pacific region is expected to exhibit the highest growth rate due to increasing healthcare spending and infrastructure investments. Key players include Terumo BCT, Fresenius Kabi, Haemonetics, and B. Braun Melsungen.